Department of Gastroenterology, Veterans Affairs Medical Center, Kansas City, MO, USA.
Gastrointest Endosc. 2012 Jan;75(1):11-8. doi: 10.1016/j.gie.2011.06.040. Epub 2011 Sep 10.
After endoscopic eradication therapy (EET) for Barrett's esophagus (BE), surveillance of residual/recurrent intestinal metaplasia/dysplasia including subsquamous tissue is performed by using biopsy forceps.
The goal of this study was to compare the adequacy of biopsy specimens obtained from neo-squamous (post-EET patients) and native (non-BE patients) squamous mucosa.
A case-control study using squamous biopsy specimens obtained at 2 tertiary referral centers was conducted.
Two experienced GI pathologists reviewed specimens from patients with neo- (post-EET patients) and native (non-BE patients) squamous mucosa in a blinded fashion after developing standardized criteria to assess tissue depth.
The primary outcome was the proportion of biopsy specimens that contained any amount of lamina propria.
A total of 193 biopsy specimens (1692 tissue pieces) from 104 patients were reviewed: 163 neo- and 30 native squamous. Of all biopsy specimens, only 37% contained any amount of lamina propria, and, furthermore, fewer than 4% of specimens had sufficient lamina propria (ie, more than two thirds of the entire squamous tissue present). When examining individual squamous tissue pieces, fewer than 11% contained lamina propria. No statistically significant differences in the presence of lamina propria were detected between neo- and native squamous mucosa.
The majority of esophageal squamous biopsy specimens obtained during endoscopy do not demonstrate lamina propria and subepithelial structures. This is true for both neo- and native squamous mucosa. Biopsy specimens of neo-squamous mucosa obtained after EET appear to be inadequate to exclude subsquamous intestinal metaplasia/dysplasia because lamina propria is not present in more than 60% of specimens. This has larger implications in the clinical management of BE patients after EET.
在内镜下根除治疗(EET)巴雷特食管(BE)后,通过活检钳对残留/复发的肠上皮化生/异型增生进行检测,包括黏膜下组织。
本研究的目的是比较新鳞状(EET 后患者)和固有(非 BE 患者)鳞状黏膜获得的活检标本的充分性。
在 2 个三级转诊中心进行了一项新鳞状(EET 后患者)和固有(非 BE 患者)鳞状黏膜活检标本的病例对照研究。
2 名经验丰富的胃肠病理学家在制定评估组织深度的标准化标准后,以盲法方式对来自新(EET 后患者)和固有(非 BE 患者)鳞状黏膜的患者标本进行了审查。
主要结局是包含任何量固有层的活检标本的比例。
共审查了 104 例患者的 193 份活检标本(1692 个组织块):163 份新鳞状和 30 份固有鳞状。所有活检标本中,仅 37%包含任何量固有层,并且不到 4%的标本具有足够的固有层(即存在的整个鳞状组织的三分之二以上)。在检查单个鳞状组织块时,不到 11%的组织块包含固有层。新鳞状和固有鳞状黏膜之间固有层的存在无统计学差异。
内镜检查期间获得的大多数食管鳞状活检标本不显示固有层和黏膜下结构。这对于新鳞状和固有鳞状黏膜都是如此。EET 后获得的新鳞状黏膜活检标本似乎不足以排除黏膜下肠上皮化生/异型增生,因为超过 60%的标本中不存在固有层。这对 EET 后 BE 患者的临床管理具有更大的影响。